EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Safety and Efficacy of Semaglutide in Kidney Transplant Recipients With Type 2 Diabetes Mellitus or Post-Transplant Diabetes Mellitus: A Retrospective Cohort Study

Issa Kawalit, Abdulraqeeb Hasan Al-Omari, Mohammed Aboalgasem, Abdulhafid Ali Shebani, Asad T. Ibrahim Alterawi, Masuda M. Eniza, Abbas Y. El-Khatib

Medical Research Archives · 31.07.2026 · 14 (7)

DOI: 10.18103/mra.2026.0406 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Medical Research Archives, online erschienen am 31.07.2026. Verfasst von Issa Kawalit und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Post-transplant diabetes mellitus and obesity are frequent metabolic complications after kidney transplantation and are associated with increased cardiovascular and graft-related risk. Glucagon-like peptide-1 receptor agonists improve glycaemic control and body weight in type 2 diabetes mellitus and obesity, but their use in kidney transplant recipients remains limited by concerns regarding gastrointestinal intolerance, dehydration-related kidney injury, hepatic safety, and possible interference with calcineurin inhibitor exposure through delayed gastric emptying.

Methods

We conducted a retrospective single-centre cohort study of 15 kidney transplant recipients with either pre-existing type 2 diabetes mellitus or post-transplant diabetes mellitus who were treated with semaglutide. Most patients had follow-up between 12 and 16 months. Primary effectiveness outcomes were changes in glycated haemoglobin and body weight. Safety outcomes included gastrointestinal adverse events, renal graft function, calcineurin inhibitor dose and trough-level stability, rejection episodes, and clinically significant adverse events.

Results

The cohort included 11 men (73.3%) and 4 women (26.7%), with a mean age of 52 +- 13 years. Eleven patients (73.3%) had pre-existing type 2 diabetes mellitus and 4 (26.7%) had post-transplant diabetes mellitus. Semaglutide was initiated approximately 6 weeks after transplantation. Mean baseline glycated haemoglobin was 8.4 +- 1.3%, and mean baseline body weight was 99.5 +- 17.7 kg. During follow-up, semaglutide was associated with clinically meaningful improvement in glycaemic control and reduction in body weight. Fourteen patients (93.3%) received tacrolimus-based immunosuppression and 1 (6.7%) received cyclosporine. Median tacrolimus dose was 3 mg/day (IQR, 2-4), and mean tacrolimus trough level was 7.5 +- 2.2 ng/mL. No clinically significant calcineurin inhibitor interaction or dose adjustment was observed. Serum creatinine remained within approximately 0.9-1.2 mg/dL, estimated glomerular filtration rate remained stable, and no excess rejection signal was identified. Adverse effects were mainly mild gastrointestinal symptoms; two patients (13.3%) discontinued therapy because of nausea. No severe pancreatitis or major treatment-related toxicity was observed.

Conclusions

In this small retrospective kidney transplant cohort, semaglutide was associated with improved metabolic outcomes without apparent adverse effects on graft function or calcineurin inhibitor exposure. Larger prospective transplant-specific studies are needed.

Zitieren

APA

Kawalit, I., Al-Omari, A. H., Aboalgasem, M., Shebani, A. A., Alterawi, A. T. I., Eniza, M. M., & El-Khatib, A. Y. (2026). Safety and Efficacy of Semaglutide in Kidney Transplant Recipients With Type 2 Diabetes Mellitus or Post-Transplant Diabetes Mellitus: A Retrospective Cohort Study. Medical Research Archives, 14(7). https://doi.org/10.18103/mra.2026.0406

Vancouver

Kawalit I, Al-Omari AH, Aboalgasem M, Shebani AA, Alterawi ATI, Eniza MM, et al. Safety and Efficacy of Semaglutide in Kidney Transplant Recipients With Type 2 Diabetes Mellitus or Post-Transplant Diabetes Mellitus: A Retrospective Cohort Study. Medical Research Archives. 2026;14(7). doi:10.18103/mra.2026.0406

BibTeX
@article{Kawalit2026,
  author = {Kawalit, Issa and Al-Omari, Abdulraqeeb Hasan and Aboalgasem, Mohammed and Shebani, Abdulhafid Ali and Alterawi, Asad T. Ibrahim and Eniza, Masuda M. and El-Khatib, Abbas Y.},
  title = {Safety and Efficacy of Semaglutide in Kidney Transplant Recipients With Type 2 Diabetes Mellitus or Post-Transplant Diabetes Mellitus: A Retrospective Cohort Study},
  journal = {Medical Research Archives},
  year = {2026},
  volume = {14},
  number = {7},
  doi = {10.18103/mra.2026.0406}
}
Kostenlos starten →